Skip to Main Content

LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental medicines that sent the company’s shares up — and those of its rivals down.

But on Thursday, company executives faced an onslaught of questions from analysts during an earnings presentation about what could come next for the company’s weight loss drugs and how they would stand apart in the wildly competitive field. Analysts asked what made the Roche drug candidates different, and how the company saw its lane given that it’s years behind other drugmakers, some of which already have products on the market.

advertisement

“It’s going to be a huge market,” said Roche CEO Thomas Schinecker, seemingly trying to reassure analysts that there would be plenty of demand for the company’s drugs.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.